SEC Comment Letter for BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497) (BRTX) — Nov 23, 2011

BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497)
Date: Nov. 23, 2011 · CIK: 0001505497 · Accession: 0000000000-11-068077

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-54402

Date

November 23, 2011

Author

/s/ Pamela Howell

Form

UPLOAD

Company

BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497)

Letter

November 23, 2011 Via E-Mail Mark Weinreb, Chief Executive Officer BioRestorative Therapies, Inc. 555 Heritage Drive Jupiter, FL 33458

Re: BioRestorative Therapies, Inc. (f/k/a Stem Cell Assurance, Inc.) Amendment No. 3 to Form 10 Filed November 14, 2011 File No. 000-54402

Dear Mr. Weinreb: We have completed our review of your f ilings. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Pamela Howell
for
John Reynolds
Assistant Director

Show Raw Text

November 23, 2011
Via E-Mail
Mark Weinreb, Chief Executive Officer BioRestorative Therapies, Inc.  555 Heritage Drive Jupiter, FL 33458

Re: BioRestorative Therapies, Inc. (f/k/a Stem Cell Assurance, Inc.)
Amendment No. 3 to Form 10 Filed November 14, 2011 File No. 000-54402

Dear Mr. Weinreb:
We have completed our review of your f ilings.  We remind you that our comments or
changes to disclosure in res ponse to our comments do not for eclose the Commission from taking
any action with respect to the company or th e filing and the company may not assert staff
comments as a defense in any proceeding ini tiated by the Commission or any person under the
federal securities laws of the United States.  We urge all pers ons who are responsible for the
accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the
information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
  /s/ Pamela Howell
 for
         John Reynolds
Assistant Director

SecProbe.io